Holdings of Fidelity Advisor Biotechnology Fund
Fidelity Advisor Series VII · Original filing · Compare with another fund · Report an error
- Net assets
- 2.2B $ including 2.1B $ in equities, 96.3 %
- Positions
- 76 in 9 countries
- Top ten
- 46.9 % of net assets
- Filed on
- Jul 31, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | AbbVie Inc | 1,289,880 | 323.7M $ | 14.71 % |
| 2 | Gilead Sciences Inc | 963,500 | 125.5M $ | 5.70 % |
| 3 | Spyre Therapeutics Inc | 857,347 | 84.3M $ | 3.83 % |
| 4 | ALNYLAM PHARMACEUTICALS INC | 387,186 | 79.6M $ | 3.62 % |
| 5 | Dianthus Therapeutics Inc | 730,062 | 78.1M $ | 3.55 % |
| 6 | COGENT BIOSCIENCES INC | 1,834,818 | 71.4M $ | 3.25 % |
| 7 | ORUKA THERAPEUTICS INC | 737,386 | 71.2M $ | 3.24 % |
| 8 | Insmed Inc | 680,300 | 67.1M $ | 3.05 % |
| 9 | REVOLUTION MEDICINES INC | 352,200 | 66M $ | 3.00 % |
| 10 | Argenx SE | 77,200 | 65.9M $ | 3.00 % |
| 11 | Ascendis Pharma A/S | 269,225 | 65.7M $ | 2.99 % |
| 12 | Biogen Inc | 294,100 | 59.7M $ | 2.71 % |
| 13 | MBX BIOSCIENCES INC | 817,600 | 53.9M $ | 2.45 % |
| 14 | Amgen Inc | 135,103 | 52M $ | 2.37 % |
| 15 | AMYLYX PHARMACEUTICALS INC | 2,433,200 | 49.4M $ | 2.25 % |
| 16 | VAXCYTE INC | 801,529 | 43.3M $ | 1.97 % |
| 17 | MODERNA INC | 640,800 | 35.1M $ | 1.60 % |
| 18 | Relay Therapeutics Inc | 1,850,700 | 34.8M $ | 1.58 % |
| 19 | VIRIDIAN THERAPEUTICS INC | 1,782,464 | 33.7M $ | 1.53 % |
| 20 | NATERA INC | 117,200 | 31.4M $ | 1.43 % |
| 21 | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | 417,600 | 31M $ | 1.41 % |
| 22 | Vertex Pharmaceuticals Inc | 63,900 | 30.5M $ | 1.39 % |
| 23 | Enliven Therapeutics Inc | 501,368 | 27.5M $ | 1.25 % |
| 24 | ALUMIS INC | 946,500 | 26.7M $ | 1.22 % |
| 25 | Roivant Sciences Ltd | 776,700 | 26.3M $ | 1.20 % |
| 26 | STRUCTURE THERAPEUTICS INC | 527,900 | 25.4M $ | 1.15 % |
| 27 | KYMERA THERAPEUTICS INC | 231,700 | 24M $ | 1.09 % |
| 28 | Praxis Precision Medicines Inc | 74,200 | 22.8M $ | 1.04 % |
| 29 | Xenon Pharmaceuticals Inc | 342,258 | 21.4M $ | 0.98 % |
| 30 | Celldex Therapeutics Inc | 512,352 | 19.5M $ | 0.89 % |
| 31 | Regeneron Pharmaceuticals Inc | 22,500 | 17.2M $ | 0.78 % |
| 32 | ZENAS BIOPHARMA INC | 491,724 | 15.5M $ | 0.70 % |
| 33 | First Tracks Biotherapeutics Inc | 341,150 | 15M $ | 0.68 % |
| 34 | MIRUM PHARMACEUTICALS INC | 135,100 | 14.3M $ | 0.65 % |
| 35 | Viking Therapeutics Inc | 450,187 | 14.3M $ | 0.65 % |
| 36 | JADE BIOSCIENCES INC | 698,671 | 13.8M $ | 0.63 % |
| 37 | NEWAMSTERDAM PHARMA COMPANY NV | 448,000 | 12.4M $ | 0.57 % |
| 38 | DYNE THERAPEUTICS INC | 482,000 | 12.1M $ | 0.55 % |
| 39 | Climb Bio Inc | 996,400 | 11.9M $ | 0.54 % |
| 40 | ARCUS BIOSCIENCES INC | 417,900 | 11.8M $ | 0.54 % |
| 41 | AVALO THERAPEUTICS INC | 639,700 | 11.7M $ | 0.53 % |
| 42 | TYRA BIOSCIENCES INC | 354,200 | 11.3M $ | 0.51 % |
| 43 | CG ONCOLOGY INC | 157,700 | 11.2M $ | 0.51 % |
| 44 | uniQure NV | 223,500 | 9.8M $ | 0.44 % |
| 45 | Stoke Therapeutics Inc | 317,700 | 9.2M $ | 0.42 % |
| 46 | Olema Pharmaceuticals Inc | 777,200 | 8.9M $ | 0.40 % |
| 47 | HEMAB THERAPEUTICS HOLDINGS INC | 186,700 | 8.9M $ | 0.40 % |
| 48 | DAMORA THERAPEUTICS INC | 298,142 | 8.6M $ | 0.39 % |
| 49 | Annexon Inc | 1,661,500 | 8.5M $ | 0.38 % |
| 50 | Mineralys Therapeutics Inc | 331,100 | 8.4M $ | 0.38 % |
| 51 | UCB SA | 32,600 | 8.4M $ | 0.38 % |
| 52 | CYTOMX THERAPEUTICS INC | 2,490,551 | 7.7M $ | 0.35 % |
| 53 | VOR BIOPHARMA INC | 343,954 | 7.3M $ | 0.33 % |
| 54 | Definium Therapeutics Inc | 161,200 | 7M $ | 0.32 % |
| 55 | TARSUS PHARMACEUTICALS INC | 110,000 | 6.5M $ | 0.30 % |
| 56 | Disc Medicine Inc | 80,922 | 6.2M $ | 0.28 % |
| 57 | Tenax Therapeutics Inc | 445,100 | 6.1M $ | 0.28 % |
| 58 | Neurogene Inc | 177,200 | 5.8M $ | 0.26 % |
| 59 | DBV Technologies SA | 428,800 | 5.8M $ | 0.26 % |
| 60 | Scholar Rock Holding Corp | 118,168 | 5.6M $ | 0.25 % |
| 61 | Edgewise Therapeutics Inc | 144,500 | 5.6M $ | 0.25 % |
| 62 | Solid Biosciences Inc | 677,565 | 5.5M $ | 0.25 % |
| 63 | INFLARX NV | 3,196,071 | 5.4M $ | 0.25 % |
| 64 | X4 Pharmaceuticals Inc | 1,341,800 | 5.3M $ | 0.24 % |
| 65 | CRESCENT BIOPHARMA INC | 356,090 | 5.2M $ | 0.23 % |
| 66 | SILENCE THERAPEUTICS PLC | 482,088 | 5.1M $ | 0.23 % |
| 67 | Janux Therapeutics Inc | 320,385 | 4.9M $ | 0.22 % |
| 68 | Madrigal Pharmaceuticals Inc | 10,300 | 4.8M $ | 0.22 % |
| 69 | AVALYN PHARMA INC | 162,100 | 4.7M $ | 0.21 % |
| 70 | Upstream Bio Inc | 691,003 | 4.4M $ | 0.20 % |
| 71 | Bridgebio Pharma Inc | 46,900 | 3.8M $ | 0.17 % |
| 72 | Kodiak Sciences Inc | 88,300 | 3.7M $ | 0.17 % |
| 73 | Contineum Therapeutics Inc | 224,900 | 3.5M $ | 0.16 % |
| 74 | Tectonic Therapeutic Inc | 120,995 | 3.4M $ | 0.15 % |
| 75 | INVENTIVA SA | 685,400 | 3.1M $ | 0.14 % |
| 76 | MAPLIGHT THERAPEUTICS INC | 202,900 | 2.6M $ | 0.12 % |
Sector breakdown
- Health care 42.3 %
- Unattributed 57.7 %
Titelia assigns each company to a sector, one by one. The unassigned share stays visible, under "Unattributed".
Currency breakdown
- USD 99.6 %
- EUR 0.4 %
Each line is counted in its quoted currency, as the fund declares it.
Country breakdown
- United States 88.8 %
- Netherlands 4.4 %
- Denmark 3.1 %
- Bermuda 1.2 %
- Canada 1.0 %
- France 0.4 %
- Cayman Islands 0.4 %
- Belgium 0.4 %
- United Kingdom 0.2 %
Shares are computed on the fund's equities only.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 64 | 1.9B $ | 88.77 % |
| 2 | Netherlands | 4 | 93.5M $ | 4.42 % |
| 3 | Denmark | 1 | 65.7M $ | 3.10 % |
| 4 | Bermuda | 1 | 26.3M $ | 1.24 % |
| 5 | Canada | 1 | 21.4M $ | 1.01 % |
| 6 | France | 2 | 8.9M $ | 0.42 % |
| 7 | Cayman Islands | 1 | 8.6M $ | 0.41 % |
| 8 | Belgium | 1 | 8.4M $ | 0.40 % |
| 9 | United Kingdom | 1 | 5.1M $ | 0.24 % |
Cite this page
Titelia. "Holdings of Fidelity Advisor Biotechnology Fund". https://titelia.com/en/funds/S000005321